Literature DB >> 30525273

The impact of apelin and relaxin plasma levels in masked hypertension and white coat hypertension.

Elias Sanidas1, Kostas Tsakalis1, Dimitrios P Papadopoulos1, Kanella Zerva1, Maria Velliou1, Despoina Perrea2, Marina Mantzourani3, Dimitrios Iliopoulos2, John Barbetseas1.   

Abstract

Masked hypertension (HTN) and white coat hypertension represent two reverse forms of clinical HTN with questionable prognostic significance. Recent evidence supports that low apelin and relaxin plasma levels contribute to vascular damage accelerating atherogenesis and predisposing to HTN and cardiovascular (CV) events. The aim of this study was to compare apelin and relaxin plasma levels between patients with masked hypertension (MH) and those with white coat HTN (WCH). Overall, 130 patients not receiving antihypertensive therapy were studied. All patients underwent 24-hour ambulatory BP monitoring (ABPM) and office BP measurements. Plasma apelin and relaxin levels were measured by ELISA method. According to BP recordings, 24 subjects had MH (group A) and 32 had WCH (group B). Apelin (200 ± 111 pg/mL vs 305 ± 127 pg/mL, P < 0.01) and relaxin (35.2 ± 6.7 pg/mL vs 46.8 ± 23.6 pg/mL, P < 0.01) plasma levels were significantly lower in patients with MH compared to those with WCH, respectively. In conclusion, our findings showed that patients with MH had significantly lower apelin and relaxin levels compared to those with WCH. This observation implies an additional prognostic role for adipokines supporting the concept that MH is closer to essential HTN whereas WCH is a more benign condition. ©2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  apelin; masked hypertension; relaxin; white coat hypertension

Mesh:

Substances:

Year:  2018        PMID: 30525273      PMCID: PMC8030513          DOI: 10.1111/jch.13449

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  37 in total

1.  Prognostic value of white-coat and masked hypertension diagnosed by ambulatory monitoring in initially untreated subjects: an updated meta analysis.

Authors:  Sante D Pierdomenico; Franco Cuccurullo
Journal:  Am J Hypertens       Date:  2010-09-16       Impact factor: 2.689

2.  How common is white coat hypertension?

Authors:  T G Pickering; G D James; C Boddie; G A Harshfield; S Blank; J H Laragh
Journal:  JAMA       Date:  1988-01-08       Impact factor: 56.272

3.  Reduced circulating apelin in essential hypertension and its association with cardiac dysfunction.

Authors:  Monika Przewlocka-Kosmala; Tomasz Kotwica; Andrzej Mysiak; Wojciech Kosmala
Journal:  J Hypertens       Date:  2011-05       Impact factor: 4.844

Review 4.  The actions of relaxin on the human cardiovascular system.

Authors:  Mohsin Sarwar; Xiao-Jun Du; Thomas B Dschietzig; Roger J Summers
Journal:  Br J Pharmacol       Date:  2016-07-11       Impact factor: 8.739

Review 5.  The Emerging Potential of the Apelin-APJ System in Heart Failure.

Authors:  Jonathan R Dalzell; John P Rocchiccioli; Robin A P Weir; Colette E Jackson; Neal Padmanabhan; Roy S Gardner; Mark C Petrie; John J V McMurray
Journal:  J Card Fail       Date:  2015-03-18       Impact factor: 5.712

Review 6.  White Coat Hypertension: to Treat or Not to Treat?

Authors:  Cesare Cuspidi; Carla Sala; Guido Grassi; Giuseppe Mancia
Journal:  Curr Hypertens Rep       Date:  2016-11       Impact factor: 5.369

7.  Incidence of cardiovascular events in white-coat, masked and sustained hypertension versus true normotension: a meta-analysis.

Authors:  Robert H Fagard; Véronique A Cornelissen
Journal:  J Hypertens       Date:  2007-11       Impact factor: 4.844

8.  Target Organ Complications and Cardiovascular Events Associated With Masked Hypertension and White-Coat Hypertension: Analysis From the Dallas Heart Study.

Authors:  Danielle Tientcheu; Colby Ayers; Sandeep R Das; Darren K McGuire; James A de Lemos; Amit Khera; Norman Kaplan; Ronald Victor; Wanpen Vongpatanasin
Journal:  J Am Coll Cardiol       Date:  2015-11-17       Impact factor: 24.094

9.  Increased long-term risk of new-onset diabetes mellitus in white-coat and masked hypertension.

Authors:  Giuseppe Mancia; Michele Bombelli; Rita Facchetti; Fabiana Madotto; Fosca Quarti-Trevano; Guido Grassi; Roberto Sega
Journal:  J Hypertens       Date:  2009-08       Impact factor: 4.844

10.  Masked hypertension and atherogenesis: the impact of apelin and relaxin plasma levels.

Authors:  Dimitris P Papadopoulos; Iordanis Mourouzis; Charles Faselis; Despina Perrea; Thomas Makris; Costas Tsioufis; Vasilios Papademetriou
Journal:  J Clin Hypertens (Greenwich)       Date:  2013-02-12       Impact factor: 3.738

View more
  3 in total

1.  The impact of apelin and relaxin plasma levels in masked hypertension and white coat hypertension.

Authors:  Elias Sanidas; Kostas Tsakalis; Dimitrios P Papadopoulos; Kanella Zerva; Maria Velliou; Despoina Perrea; Marina Mantzourani; Dimitrios Iliopoulos; John Barbetseas
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-12-07       Impact factor: 3.738

2.  New vascular biomarkers related to ABPM phenotypes in untreated patients.

Authors:  Luis M Ruilope; Gema Ruiz-Hurtado
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-12-07       Impact factor: 3.738

Review 3.  Relaxin-2 as a Potential Biomarker in Cardiovascular Diseases.

Authors:  Alana Aragón-Herrera; Sandra Feijóo-Bandín; Laura Anido-Varela; Sandra Moraña-Fernández; Esther Roselló-Lletí; Manuel Portolés; Estefanía Tarazón; Oreste Gualillo; José Ramón González-Juanatey; Francisca Lago
Journal:  J Pers Med       Date:  2022-06-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.